ZA200100226B - Compounds and compositions for delivering active agents. - Google Patents
Compounds and compositions for delivering active agents. Download PDFInfo
- Publication number
- ZA200100226B ZA200100226B ZA200100226A ZA200100226A ZA200100226B ZA 200100226 B ZA200100226 B ZA 200100226B ZA 200100226 A ZA200100226 A ZA 200100226A ZA 200100226 A ZA200100226 A ZA 200100226A ZA 200100226 B ZA200100226 B ZA 200100226B
- Authority
- ZA
- South Africa
- Prior art keywords
- hormone
- active agent
- heparin
- molecular weight
- composition
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims description 68
- 239000000203 mixture Substances 0.000 title claims description 61
- 150000001875 compounds Chemical class 0.000 title claims description 38
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 36
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 23
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 23
- 229960001319 parathyroid hormone Drugs 0.000 claims description 23
- 239000000199 parathyroid hormone Substances 0.000 claims description 23
- 239000000122 growth hormone Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 102000003951 Erythropoietin Human genes 0.000 claims description 20
- 108090000394 Erythropoietin Proteins 0.000 claims description 20
- -1 adrcnocorticotropin Chemical compound 0.000 claims description 20
- 229940105423 erythropoietin Drugs 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 19
- 229920000669 heparin Polymers 0.000 claims description 19
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 19
- 229960002897 heparin Drugs 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 102000004877 Insulin Human genes 0.000 claims description 16
- 108090001061 Insulin Proteins 0.000 claims description 16
- 229940125396 insulin Drugs 0.000 claims description 16
- 239000003055 low molecular weight heparin Substances 0.000 claims description 16
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 14
- 229960000958 deferoxamine Drugs 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 11
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 10
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 10
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 10
- 102000055006 Calcitonin Human genes 0.000 claims description 9
- 108060001064 Calcitonin Proteins 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 239000003488 releasing hormone Substances 0.000 claims description 8
- 108010051696 Growth Hormone Proteins 0.000 claims description 7
- 102000018997 Growth Hormone Human genes 0.000 claims description 7
- 102000014150 Interferons Human genes 0.000 claims description 7
- 108010050904 Interferons Proteins 0.000 claims description 7
- 102400000050 Oxytocin Human genes 0.000 claims description 7
- 101800000989 Oxytocin Proteins 0.000 claims description 7
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 7
- 108010059993 Vancomycin Proteins 0.000 claims description 7
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 7
- 108010004977 Vasopressins Proteins 0.000 claims description 7
- 102000002852 Vasopressins Human genes 0.000 claims description 7
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 7
- 229960004015 calcitonin Drugs 0.000 claims description 7
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 7
- 229960001723 oxytocin Drugs 0.000 claims description 7
- 229960003165 vancomycin Drugs 0.000 claims description 7
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 7
- 229960003726 vasopressin Drugs 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
- 102000000589 Interleukin-1 Human genes 0.000 claims description 5
- 108010002352 Interleukin-1 Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102000005157 Somatostatin Human genes 0.000 claims description 5
- 108010056088 Somatostatin Proteins 0.000 claims description 5
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 239000003429 antifungal agent Substances 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 230000001746 atrial effect Effects 0.000 claims description 5
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 5
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 5
- 229940047124 interferons Drugs 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 5
- 229960000553 somatostatin Drugs 0.000 claims description 5
- 101800000414 Corticotropin Proteins 0.000 claims description 4
- 229920001499 Heparinoid Polymers 0.000 claims description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 4
- 229960000258 corticotropin Drugs 0.000 claims description 4
- 239000002554 heparinoid Substances 0.000 claims description 4
- 229940025770 heparinoids Drugs 0.000 claims description 4
- 229920002567 Chondroitin Polymers 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 229930105110 Cyclosporin A Natural products 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 3
- 108010029961 Filgrastim Proteins 0.000 claims description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 3
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 3
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 3
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 3
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 3
- 239000000854 Human Growth Hormone Substances 0.000 claims description 3
- 102000013275 Somatomedins Human genes 0.000 claims description 3
- 102000036693 Thrombopoietin Human genes 0.000 claims description 3
- 108010041111 Thrombopoietin Proteins 0.000 claims description 3
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 229960004177 filgrastim Drugs 0.000 claims description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 150000003180 prostaglandins Chemical class 0.000 claims description 3
- 108010068072 salmon calcitonin Proteins 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims 8
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 4
- 108010006025 bovine growth hormone Proteins 0.000 claims 3
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 claims 2
- 239000004698 Polyethylene Substances 0.000 claims 2
- 229940045644 human calcitonin Drugs 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 230000000849 parathyroid Effects 0.000 claims 2
- 229920000573 polyethylene Polymers 0.000 claims 2
- JDJALSWDQPEHEJ-LMVCGNDWSA-N x4853 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 JDJALSWDQPEHEJ-LMVCGNDWSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 description 42
- 239000000243 solution Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- 230000004888 barrier function Effects 0.000 description 11
- 230000002685 pulmonary effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- RFIBGZVQUQSCEW-UHFFFAOYSA-N 2-[4-[(2-hydroxybenzoyl)amino]phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1NC(=O)C1=CC=CC=C1O RFIBGZVQUQSCEW-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108010005991 Pork Regular Insulin Proteins 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- NIORKUCQYOETJT-UHFFFAOYSA-M sodium;2-[4-[(2-hydroxybenzoyl)amino]phenyl]propanoate Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1NC(=O)C1=CC=CC=C1O NIORKUCQYOETJT-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- 235000006491 Acacia senegal Nutrition 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- LSKOJLKNJUNBAC-UHFFFAOYSA-N 2-benzamidoacetyl chloride Chemical compound ClC(=O)CNC(=O)C1=CC=CC=C1 LSKOJLKNJUNBAC-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- CIYPNZYEUZQIHN-UHFFFAOYSA-N cycloheptanecarbonyl chloride Chemical compound ClC(=O)C1CCCCCC1 CIYPNZYEUZQIHN-UHFFFAOYSA-N 0.000 description 2
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 2
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 229940108519 trasylol Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DSGKWFGEUBCEIE-UHFFFAOYSA-N (2-carbonochloridoylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1C(Cl)=O DSGKWFGEUBCEIE-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- WOMVICAMAQURRN-UHFFFAOYSA-N 2-(4-aminophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(N)C=C1 WOMVICAMAQURRN-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- GVOUFPWUYJWQSK-UHFFFAOYSA-N Cyclofenil Chemical group C1=CC(OC(=O)C)=CC=C1C(C=1C=CC(OC(C)=O)=CC=1)=C1CCCCC1 GVOUFPWUYJWQSK-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- XJLATMLVMSFZBN-VYDXJSESSA-N actinonin Chemical compound CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO XJLATMLVMSFZBN-VYDXJSESSA-N 0.000 description 1
- XJLATMLVMSFZBN-UHFFFAOYSA-N actinonine Natural products CCCCCC(CC(=O)NO)C(=O)NC(C(C)C)C(=O)N1CCCC1CO XJLATMLVMSFZBN-UHFFFAOYSA-N 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960002944 cyclofenil Drugs 0.000 description 1
- JOHUAELJNSBTGS-UHFFFAOYSA-N cyclohexanecarbonyl cyclohexanecarboxylate Chemical compound C1CCCCC1C(=O)OC(=O)C1CCCCC1 JOHUAELJNSBTGS-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
The present invention relates to compounds for delivering active agents, and particularly biologically or chemically active agents. These compounds are used as carriers to facilitate the delivery of an active agent to a target. The carrier compounds are well suited to form non-covalent mixtures with biologically-active agents for pulmonary, oral, subcutaneous, intranasal, sublingual, buccal, ocular, intracolonic, intraduodenal, rectal, vaginal, mucosal, transdermal, intradermal, parenteral, intravenous, and intramuscular administration to animals, ) as well as crossing the blood-brain barrier. Methods for the preparation and administration of such compositions are also disclosed.
Conventional means for delivering active agents are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through which delivery occurs, the environment of the target for delivery, or the target itself. Biologically or chemically active agents are particularly vulnerable to such barriers.
For example, in the delivery to animals of biologically active or chemically active pharmacological and therapeutic agents, barriers are imposed by the body. Examples of physical barriers are the skin and various organ membranes that must be traversed before reaching a target.
Chemical barriers include, but are not limited to, pH variations, lipid bi-layers, and degrading enzymes.
These barriers are of particular significance in the design of drug delivery systems.
For example, oral delivery of many biologically or chemically active agents would be alternate routes of choice for administration to animals if not for biological, chemical, and physical barriers such as varying pH in the gastro-intestinal membranes. Among the numerous agents which are not typically amenable to oral administration are biologically or chemically active peptides, such as calcitonin and insulin; polysaccharides, and in particular mucopolysaccharides including, but not limited to, heparin; heparinoids; antibiotics; and other organic substances. These agents are rapidly rendered ineffective or are destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes, and the like. In addition, the size and structure of macromolecular drugs may prohibit absorption.
Crossing the blood-brain barrier, as well as oral, subcutaneous, intranasal, sublingual, buccal, ocular, intracolonic, intraduodenal, mucosal, transdermal or pulmonary delivery to the circulatory system for many biologically active agents could be the route of choice for administration to animals if not for physical barriers such as the skin, lipid bi-layers, and various organ membranes that are relatively impermeable to certain biologically active agents, but one or more of which must be traversed before an agent delivered via these routes can reach the circulatory system. Additionally, delivery such as, for example, sublingual delivery may be impeded by chemical barriers such as the varying pH in the gastrointestinal (GI) tract and the presence of powerful digestive enzymes.
Earlier methods for orally administering vulnerable pharmacological agents have } relied on the co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) to increase artificially the permeability of the intestinal walls, as well as the co-administration of enzymatic inhibitors (e.g, pancreatic trypsin inhibitors, diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymatic degradation.
Liposomes have also been described as drug delivery systems for insulin and heparin. See, for example, U.S. Patent No. 4,239,754; Patel er al. (1976), FEBS Letters, Vol. 62, pg. 60; and Hashimoto er al. (1979), Endocrinology Japan, Vol. 26, pg. 337.
However, broad spectrum use of such drug delivery systems is precluded because: (1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight cargos, i.e. active agents, are not available; (3) the systems exhibit poor stability and inadequate shelf life; (4) the systems are difficult to manufacture; (5) the systems fail to protect the active agent (cargo); (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent.
oo © WD 00/06534 PCT/US99/17090 rs
More recently, microspheres of artificial polymers of mixed amino acids (proteinoids) have been used to deliver pharmaceuticals. For example, U.S. Patent No. 4,925,673 describes drug-containing proteinoid microsphere carriers as well as methods for their preparation and use. These proteinoid microspheres are useful for the delivery of a number of active agents.
However, there is still a need for simple, inexpensive delivery systems which are easily prepared and which can deliver a broad range of active agents by various routes.
The present invention provides compounds having the formula i
N
O
0 OH
HO
: and salts thereof. These compounds are useful in the delivery of active agents.
Another embodiment of the invention is a composition comprising: ) (A) at least one active agent; and (B) a carrier comprising a compound having the formula
I
N
O
0 OH
HO or a salt thereof.
Also provided are dosage unit forms comprising the composition above and an excipient, a diluent, a disintegrant, a lubricant, a plasticizer, a colorant, a dosing vehicle, or any combination thereof.
Methods for administering a biologically-active agent to an animal in need of the agent by the pulmonary, oral, subcutaneous, intranasal, sublingual, buccal, ocular, intracolonic, intraduodenal, rectal, vaginal, mucosal, transdermal, intradermal, parenteral, intravenous, or intramuscular route or crossing the blood-brain barrier with the compositions of the present invention are also provided.
Figure 1 is a graphical illustration of blood glucose levels after pulmonary delivery of insulin.
Figure 2 is a graphical illustration of blood glucose levels after pulmonary delivery of insulin.
One group of compositions of the present invention include an active agent and a carrier which includes the compound 2-(4-(N-salicyloyl)aminophenyl)propionic acid or salts thereof, such as the sodium salt thereof (sodium 2-(4-(N-salicyloyl)aminophenyl)propionate).
These compositions may be used to deliver various active agents through various biological, chemical, and physical barriers and are particularly suited for delivering active agents which are subject to environmental degradation. The compositions of the subject invention are particularly useful for delivering or administering biologically or chemically active agents to any animals such as birds, including, but not limited to, chickens: mammals, such as primates, and particularly i humans; and insects.
Other advantages of the present invention include the use of easy to prepare, inexpensive raw materials. The compositions and the formulation methods of the present invention are cost effective, simple to perform, and amenable to industrial scale up for commercial production.
Pulmonary, oral, subcutaneous, intranasal, sublingual, buccal, ocular, intracolonic, intraduodenal, rectal, vaginal, mucosal, transdermal, intradermal, parenteral, intravenous, and intramuscular coadministration of an active agent, such as, for example, recombinant human growth hormone (rhGH); salmon calcitonin; insulin heparin, including, but not limited to, low molecular weight heparin and very low molecular weight heparin; parathyroid hormone (PTH); and compounds in compositions as described herein result in an increased bioavailability of the active agent compared to administration of the active agent alone.
©. WO 00/06534 PCT/US99/17090 >
Active Agents
Active agents suitable for use in the present invention include biologically and chemically active agents including, but not limited to, cosmetics, pesticides, pharmacological agents, and therapeutic agents. For example, biologically or chemically active agents suitable for use in the present invention include, but are not limited to, proteins; polypeptides; peptides, and particularly small peptides; hormones, and particularly hormones which by themselves do not or only a fraction of the administered dose passes through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastro-intestinal tract; polysaccharides, and particularly mixtures of much-polysaccharidcs; carbohydrates; lipids; other organic compounds; or any combination thereof. Further examples include, but are not limited to, the following, including synthetic, natural or recombinant sources thereof: growth hormones, including human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, and porcine growth hormones; growth hormone-releasing hormones; interferons, includinga, B and yY; interleukin-1; interleukin-II; insulin;insulin-like growth factor, including IGF-1; heparin, including unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin and ultra low molecular weight heparin, calcitonin, including salmon, eel and human; erythropoietin (EPO); atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; protease inhibitors; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; leutinizing-hormone-releasing-hormone; follicle stimulating hormone; glucocerebrosidase; thrombopoietin; filgrastim; prostaglandins; cyclosporin; vasopressin; cromolyn sodium (sodium or disodium chromoglycate); vancomycin; desferrioxamine (DFO); parathyroid hormone (PTH), including its fragments; antimicrobials, including anti-fungal agents; analogs, fragments, mimetics or polyethylene glycol (PEG)-modified derivatives of these compounds; or any combination thereof,
a
Carriers
The carrier compounds of the present invention include
I
N
Oo OH
HO
2-(4-(N-salicyloyl)aminophenyl)propionic acid and salts thereof. Salts of the compound include, but are not limited to, organic or inorganic salts, such as the sodium salt:
H
.
O
NaO :
Sodium-2-(4-(N-salicyloyl)aminophenyl)propionate
In addition, carriers of the present invention include poly amino acids and peptides comprising one or more of the carrier compounds of the present invention.
These carrier compounds, poly amino acids, and peptides may be used to deliver active agents including, but not limited to, biologically or chemically active agents, such as for example, pharmacological and therapeutic agents.
An amino acid is any carboxylic acid having at least one free amine group and includes naturally occurring and synthetic amino acids.
Poly amino acids are either peptides or two or more amino acids linked by a bond formed by other groups which can be linked, e.g., an ester, anhydride, or an anhydride linkage.
Peptides are two or more amino acids joined by a peptide bond. Peptides can vary
© WO 00/06534 PCT/US99/17090 in length from dipeptides with two amino acids to polypeptides with several hundred amino acids.
See Chambers Biological Dictionary, editor Peter M.B. Walker, Cambridge, England: Chambers
Cambridge, 1989, page 215. Special mention is made of di-peptides, tri-peptides, tetra-peptides, and penta-peptides.
The carriers described herein may be derived from amino acids and can be readily prepared from amino acids by methods within the skill of those in the art based upon the present disclosure and the methods described in W096/30036, W097/36480, US 5,643,957 and US 5,650,386. For example, the compounds may be prepared by reacting the single amino acid, mixtures of two or more amino acids, or amino acid esters with the appropriate acylating or amine- modifying agent, which reacts with a free amino moiety present in the amino acid to form amides.
Protecting groups may be used to avoid unwanted side reactions as would be known to those skilled in the art. With regard to protecting groups, reference is made to T.W. Greene, Protecting Groups in Organic Synthesis, Wiley, New York (1981), the disclosure of which is hereby incorporated herein by reference.
Suitable, but not limiting, examples of acylating agents useful in preparing an acylated amino acids include the acid chloride acylating agents having the formula 0
Rix wherein R' is an appropriate group for the modified amino acid being prepared, such as, but not limited to, alkyl, alkenyl, cycloalkyl, or aromatic, and particularly methyl, ethyl, cyclohexyl, cyclophenyl, phenyl, or benzyl, and X is a leaving group. Typical leaving groups include, but are not limited to, halogens such as chlorine, bromine and iodine.
Examples of the acylating agents include. but are not limited to, acyl halides including, but not limited to, acetyl chloride, propyl chloride, cyclohexanoyl chloride, cyclopentanoyl chloride, and cycloheptanoyl chloride, benzoyl chloride, hippuryl chloride and the like; and anhydrides, such as acetic anhydride, propyl anhydride, cyclohexanoic anhydride, benzoic anhydride, hippuric anhydride and the like. Preferred acylating agents include benzoyl chloride. hippuryl chloride, acetyl chloride, cyclohexanoyl chloride, cyclopentanoyl chloride, and cycloheptanoyl chloride.
The amine groups can also be modified by the reaction of a carboxylic acid with coupling agents such as the carbodiimide derivatives of amino acids, particularly hydrophilic amirio acids such as phenylalanine, tryptophan, and tyrosine. Further examples include dicyclohexylcarbodiimide and the like.
Ifthe amino acid is multifunctional, i.e., has more than one -OH. -NH, or -SH group, then it may optionally be acylated at one or more functional groups to form, for example, an ester, amide, or thioester linkage.
For example, in the preparation of many acylated amino acids, the amino acids are dissolved in an aqueous alkaline solution of a metal hydroxide, e.g., sodium or potassium hydroxide and the acylating agent added. The reaction time can range from about 1 hour to about 4 hours, preferably about 2 to about 2.5 hours. The temperature of the mixture is maintained at a temperature generally ranging between about 5° C and about 70°C., preferably between about 10° C. and about 50°C. The amount of alkali employed per equivalent of NH, groups in the amino acids generally ranges between about 1.25 moles and about 3 moles, and is preferably between about 1.5 moles and about 2.25 moles per equivalent of NH,. The pH of the reaction solution generally ranges between about pH 8 and about pH 13, and is preferably between about pH 10 and about pH 12. The amount of amino modifying agent employed in relation to the quantity of amino acids is based on the moles of total free NH, in the amino acids. In general, the amino modifying agent is employed in an amount ranging between about 0.5 and about 2.5 mole equivalents, preferably between about 0.75 and about 1.25 equivalents, per molar equivalent of total NH, groups in the amino acids.
The modified amino acid formation reaction is typically quenched by adjusting the pH of the mixture with a suitable acid, e.g., concentrated hydrochloric acid, until the pH reaches between about 2 and about 3. The mixture separates on standing at room temperature to form a transparent upper layer and a white or off-white precipitate. The upper layer is discarded. and modified amino acids are collected by filtration or decantation. The crude modified amino acids are then mixed with water. Insoluble materials are removed by filtration, and the filtrate is dried in vacuo. The yield of modified amino acids generally ranges between about 30 and about 60%, and usually about 45%. The present invention also contemplates amino acids which have been modified by multiple acylation, e.g., diacylation, triacylation, etc.
If amino acid esters or amides are the starting materials, they are dissolved in a suitable organic solvent such as dimethy1formamide or pyridine, and are reacted with the amino modifying agent at a temperature ranging between about 5°C. and about 70° C, preferably about 250°C, for a period ranging between about 7 and about 24 hours. The amount of amino modifying to WO 00/06534 PCT/US99/17090
S agents used relative to the amino acid esters are the same as described above for amino acids. } Thereafter, the reaction solvent is removed under negative pressure, and optionally, the ester or amide functionality can be removed by hydrolyzing the modified amino acid ester with a suitable alkaline solution, €.g., IN sodium hydroxide, at a temperature ranging between about 50°C, and about 80°C., preferably about 70°C., for a period of time sufficient to hydrolyze off the ester group and form the modified amino acid having a free carboxyl group. The hydrolysis mixture is then cooled to room temperature and acidified, e.g, with an aqueous 25% hydrochloric acid solution, to a pH ranging between about 2 and about 2.5. The modified amino acid precipitates out of solution and is recovered by conventional means such as filtration or decantation.
The modified amino acids may be purified by acid precipitation, recrystallization, or fractionation on one or more solid chromatographic supports, alone or linked in tandem. Suitable recrystallization solvent systems include, but are not limited to, acetonitrile, methanol, and tetrahydrofuran. Fractionation may be performed on a suitable chromatographic support such as silica gel or alumina, using solvent mixtures such as methanol/n-propanol mixtures or acetic acid/butanol/water mixtures as the mobile phase; reverse phase column supports using trifluoroacetic acid./acetonitrile mixtures as the mobile phase, and ion exchange chromato graphy using water as the mobile phase. When anion exchange chromatography is performed, preferably a 0-500 mM sodium chloride gradient is employed. The modified amino acids may also be purified by extraction with ) a lower alcohol such as methanol, butanol, or isopropanol to remove impurities such as inorganic salts.
The modified amino acids generally are soluble in alkaline aqueous solution (pH=9.0); partially soluble in ethanol, n-butanol and 1:1 (v/v) toluene/ethanol solution; and insoluble in neutral water. The alkali metal salts, e.g, the sodium salts of the modified amino acids, are generally soluble in water at about a pH of 6-8.
In poly amino acids or peptides, one or more of the amino acids may be modified acylated and/or sulfonated. Poly amino acids and peptides may include one or more acylated amino acid(s). Although linear modified poly amino acids and peptides will generally include only one acylated amino acid, other poly amino acid and peptide configurations can include more than one acylated amino acid. Poly amino acids and peptides can be polymerized with the acylated amino acid(s) or can be acylated after polymerization.
Delivery systems A
The compositions of the present invention may include one or more active agents,
In one embodiment, the compounds above or salts of these compounds or poly amino acids or peptides that include at least one of these compounds or salts may be used directly as a delivery carrier by simply mixing one or more compounds or salts, poly amino acids or peptides with the active agent prior to administration.
The administration mixtures are prepared by mixing an aqueous solution of the carrier with an aqueous solution of the active ingredient, just prior to administration. Alternatively, the carrier and the biologically or chemically active ingredient can be admixed during the manufacturing process. The solutions may optionally contain additives such as phosphate buffer salts, citric acid, acetic acid, gelatin, and gum acacia.
Stabilizing additives may be incorporated into the carrier solution. With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution. The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5% (w/v), preferably about 0.5% (w/v). Suitable, but non-limiting examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, carboxylic acids and salts thereof, and polylysine. The preferred stabilizing additives are gum acacia, gelatin, and methyl! cellulose.
The amount of active agent is an amount effective to accomplish the purpose of the particular active agent for the target indication. The amount of active agent in the compositions typically 1s a pharmacologically, biologically, therapeutically, or chemically effective amount. }
However, the amount can be less than a pharmacologically, biologically, therapeutically, or chemically effective amount when the composition is used in a dosage unit form, such as a capsule, a tablet, a powder, or a liquid, because the dosage unit form may contain a plurality of carrier/biologically or chemically active agent compositions of may contain a divided pharmacologically, biologically, therapeutically, or chemically effective amount. The total effective amount can then be administered in cumulative units containing, in total, pharmacologically, biologically, therapeutically or chemically active amounts of biologically or pharmacologically active agent.
The total amount of active agent, and particularly biologically or chemically active agent, to be used can be determined by those skilled in the art. However, it has surprisingly been found that with some biologically or chemically active agents, the use of the presently disclosed carriers provides extremely efficient delivery, particularly in oral, intranasal, sublingual,
Co WO 00/06534 PCT/US99/17090 ~ intraduodenal, subcutaneous, buccal, intracolonic, rectal, vaginal, mucosal, pulmonary, transdermal, intradermal, parenteral, intravenous, intramuscular, and ocular systems, as well as traversing the blood-brain barrier. Therefore, lower amounts of biologically or chemically active agents than those used in prior dosage unit forms or delivery systems can be administered to the subject, while still achieving the same blood levels and therapeutic effects.
The amount of carrier in the present compositions is a delivery effective amount and can be determined for any particular carrier or biologically or chemically active agent by methods known to those skilled in the art. The effective amounts of the active agent and carrier in the composition may vary over a considerable range and is dependent upon the age, weight, sex, sensitivity, medical history, and the like of the individual. Clearly, it is necessary to take into account the nature of the active agent and carrier, the specific activity of the agent (units of bioactivity/mass), and its rate of absorption in the gastrointestinal tract, all of which contribute to a determination of the therapeutically effective dose.
Following administration, the active agent present in the composition or dosage unit form is rapidly taken up into the circulation. The bioavailability of the ingested agent is readily assessed by measuring a known pharmacological activity in blood, e.g. an increase in blood clotting time caused by heparin, or a decrease in circulating calcium levels caused by calcitonin.
Dosage unit forms can also include any of excipients, diluents, disintegrants, ) lubricants, plasticizers, colorants, flavorants, taste-masking agents, sugars, sweeteners, salts, and dosing vehicles, including, but not limited to water, 1,2-propane diol, ethanol, olive oil, or any combination thereof.
The delivery compositions of the present invention may also include one or more enzyme inhibitors. Such enzyme inhibitors include, but are not limited to, compounds such as actinonin or epiactinonin and derivatives thereof. Derivatives of these compounds are disclosed in
U.S. Patent No. 5,206,384, the disclosure of which is hereby incorporated herein by reference. Other enzyme inhibitors include, but are not limited to, aprotinin (Trasylol) and Bowman-Birk inhibitor.
The system is particularly advantageous for delivering chemically or biologically active agents which would otherwise be destroyed or rendered less effective by conditions encountered before the active agent reaches its target zone (i.e. the area in which the active agent of the delivery composition is to be released) and within the body of the animal to which they are administered. Particularly, the present invention is useful in pulmonary administration, such zs by an inhaler, of active agents, especially those which are not ordinarily deliverable by that route or
) those for which improved delivery is desired. Improved delivery may be faster delivery or greater delivery in a given time period.
The following examples illustrate the invention without limitation. All parts are given by weight unless otherwise indicated.
Example 1 - Preparation of 2-(4-(N-salicyloyl)aminophenyl) propionic acid
A slurry of 58.6 g (0.355 mol) of 2-(4-aminophenyl)propionic acid and 500 ml of methylene chloride was treated with 90.11 m1 (77.13 g. 0-710 mol) of trimethylsilyl chloride and was heated to reflux for 120 min. The reaction mixture was cooled to 0°C and treated with 184.44 mi (107.77 g, 1.065 mol) of triethylamine. After stirring for 5 minutes, this mixture was treated with a solution of 70.45 g (0.355 mol) of O-acetylsalicyloyl chloride and 150 ml of methylene chloride.
The reaction mixture was warmed to 25°C and stirred for 64 hr. The volatiles were removed in vacuo. The residue was stirred in 2N aqueous sodium hydroxide for one hour and acidified with 2
M aqueous sulfuric acid. The solid was recrystallized twice from ethanol/water to give a tan solid.
Isolation by filtration afforded 53.05 g of (52% yield) of 2-(4-(N -salicyloyl)aminophenyl)propionic acid. }
Properties. Solubility: 200 mg/ml: 200 mg + 350 ul 2N NaOH + 650 ul H,O - pH - 7.67. Anal. calculated for - C:67.36, H: 5.3, N: 4.91. Found - C: 67.05, H: 5.25, N: 4.72. )
Example 2 - Preparation of Sodium 2-(4-(N-salicyloyl)aminophenyl)propionate
A solution of 53.05 g (0.186 mol) of 2-(4-(N-salicyloyl)aminophenyl)propionic acid and 300 ml of ethanol was treated with 7.59 g (0.190 mol) of NaOH dissolved in 22 ml of water.
The reaction mixture was stirred for 30 min at 25C and for 30 min at 0°C. The resultin g pale yellow solid was isolated by filtration to give 52.61 g of sodium 2-(4-(N-salicyloyl)aminophenyl)propionate.
Properties. Solubility: 200 mg/ml clear solution, pH=6.85. Anal. calculated for -C: 60.45, H: 5.45,N: 3.92, Na: 6.43. Found - C: 60.84, H: 5.87, N: 3.85, Na: 6.43. Melting point 236-238°C.
Co © WO 00/06534 PCT/US99/17090 -
Example 3
A pulmonary delivery dosing composition of 0.1 mg/kg of porcine insulin and 7.5 mg/kg of the compound of Example 2 in water was prepared. A0.3 ml/kg dose of the pulmonary dosing composition at pH 7.3-7.6 was administered to five normal, non-fasting rats by the following procedure. 1%: Popper and Sons gavage needles were inserted about a few centimeters down the animals’ throats. The tip of the needed was manipulated towards the animals’ ventral sides where the needle could fall into a pocket and then with further manipulation the trachea. Once the needle was in the trachea, the dosing solution was delivered through the needle.
Periodic blood samples were drawn via the tail artery, and blood glucosc levels were measured using Ektachem DT slides (Johnson & Johnson Clinical Diagnostics, Inc., Rochester
N.Y).
Results are illustrated in Figure 1.
Comparative Example 3A
The procedure of Example 3 was followed, substituting a dosing composition of 0.1 mg/kg of porcine insulin and water for the dosing composition.
Results are illustrated in Figure 1.
Comparative Example 3B
The procedure of Example 3 was followed, substituting a dosing solution of 7.5 mg/kg of the compound prepared in Example 1 in water for the dosing solution.
Results are illustrated in Figure 1.
Example 4
The procedure of Example 3 was followed, substituting a dosing composition of 0.5 mg/kg of porcine insulin and 7.5 mg/kg of the compound prepared in Example 2, in water for the dosing composition at pH 6.6-6.9.
Results are illustrated in Figure 2.
Comparative Example 4A
The procedure of Example 4 was followed, substituting a dosing composition of 0.5 mg/kg of porcine insulin in water for the dosing composition.
»
Results are illustrated in Figure 2.
Comparative Example 4B
The procedure of Example 4 was followed, substituting a dosing composition of 7.5 mg/kg of the compound prepared in Example 2 in water for the dosing solution.
Results are illustrated in Figure 2.
Example 5
A dosing composition of 300 mg/kg of the compound prepared in Examples 2 and 3 mg/kg of human insulin in water at pH 7.02 was prepared. Strept catherized rats were dosed by oral gavage with 1 ml/kg of the dosing composition. Blood glucose levels (mg/dL) were measured.
Results are illustrated in Table 1 below.
Table 1
Time (hrs): 0.5 1 2 3 4
Assay: -44.9 -42.59 [-37.58 [36.62 -29.88
SD: 13.88 28.33 30.87 206.27 18.61
Example 6
A dosing composition of 300 mg/kg of the compound prepared in Example 1 and 100
Mg/kg of the N-terminal fragment of parathyroid hormone (amino acids 1-34) in water at pH 8.13 was prepared. Normal rats were dosed by oral gavage with 1 ml/kg of the dosing composition.
Serum levels of parathyroid hormone (pg/mL) were measured.
Results are illustrated in in Table 2 below.
Table 2
Time (mins): 15 30 45 60 90
Assay: 1522.53 886.5 786.46 711.6 482.46
SD: 538.5 272.21 239.78 181.65 329.78 rh
Example 7
A dosing composition of 100 mg/kg of the compound prepared in Ex ample 1 and 200 ug/kg of the N-terminal fragment of parathyroid hormone (amino acids 1-34) in water at pH 7.65 was prepared. Normal rats were dosed by oral gavage with 1 mg/kg of the dosing composition.
Serum levels of parathyroid hormone (pg/mL)were measured.
Results are illustrated in Table 3 below.
Table 3
Time (mins): 15 30 45 60 90
Assay: 929.6 767.27 986.79 411.03 356.8
SD: 693.18 525.18 1211.9 136.15 61.13
Example 8
The method of Example 7 was followed but the pH of the dosing composition was 7.55.
Results are illustrated in Table 4 below.
Table 4 } Time (min): 15 30 45 60 90
Assay: 976.79 711.42 610.78 520.51 516.19
SD: 388.07 244.89 218.16 78.31 37.6
Example 9 - Pulmonary Insulin Deliver
The carrier compound 2-(4-(N-salicyloyl)aminophenyl) propionic acid was tested as follows. Each rat was weighed and identified using an indelible marker and anesthetized by intramuscular injection of thorazine (3 mg/kg) and ketamine (44 mg/kg).
An endotracheal tube (spray instillator from Penn Century of Philadelphia, PA) with a syringe (Hamilton syringe) attached to the endotracheal tube was inserted using a fiber optic laryngoscope. The syringe (Hamilton syringe) of the instillator was used to instill insulin (0.03 mg/kg) and a carrier compound (16 mg/kg) into the lower portions of the airway. The endotracheal tube was removed following administration, and the breathing rate was monitored throughout the remainder of the study.
Blood samples were withdrawn at 0, 5, 15, 30, 60, and 120 minutes via the tail artery and assayed with a DSL Insulin Kit #10-1600 following the procedure outlined in the kit. The Cra value with the carrier was 44.6 + 10.0. The C,_, value without the carrier was 19.4 + 4.3.
Example 10 - Recombinant Human Growth Hormone (rhGH) Oral Delivery
Oral gavage (PO) dosing solutions containing 200 mg/kg carrier compound 2-(4-(N- salicyloyl)aminophenyl) propionic acid and 3 mg/kg rhGH in 100% phosphate buffer were prepared by mixing. The pH of the solutions ranged from about 7.67 to about 8.09.
Male Sprague-Dawley rats weighing 200-250 g were fasted for 24 hours and administered ketamine (44 mg/kg) and chlorpromazine (1.5 mg/kg) 15 minutes prior to dosing. The rats were administered 1 ml/kg of the dosing solution by PO. Blood samples were collected parenterally from the tail artery for determination of serum rHGH concentrations. Serum rHGH concentrations were quantified by an rHGH immunoassay test kit (Kit # K1F4015 from Genzyme
Corporation Inc., Cambridge, MA). The mean peak serum concentration of thGH was 93 + 74 ng/ml.
Example 11 - Erythropoietin (EPO) Oral Delivery
Oral gavage (PO) dosing solutions containing 200 mg/kg carrier compound 2-(4-(N- } salicyloyl)aminophenyl) propionic acid and 1 mg/kg human erythropoietin quantikine IUD in 100% water were prepared by mixing. The pH of the solutions ranged from about 6.9 to about 7.9.
Male Sprague-Dawley rats weighing 200-250 g were fasted for 24 hours and administered ketamine (44 mg/kg) and chlorpromazine (1.5 mg/kg) 15 minutes prior to dosing. The rats were administered 1 ml/kg of the dosing solution by PO. Blood samples were collected parenterally from the tail artery for determination of serum EPO concentrations. Serum EPO concentrations were quantified by an Elisa assay test kit (Kit #DEPOO from R&D Systems,
Minneapolis, MN). The mean peak serum concentration of EPO was 163 + 136 ng/ml.
The procedure was repeated without the carrier compound. The mean peak serum concentration of EPO was 0 ng/ml.
Co WO 00/06534 PCT/US99/17090
J The above mentioned patents, applications, test methods, and publications are hereby incorporated by reference in their entirety.
Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. All such obvious variations are within the full intended scope of the appended claim.
Claims (1)
- \ WHAT IS CLAIMED IS:1 1. A compound having the formula 2 3 H ; 0 6 0 OH 8 9 or a salt thereof.1 2. A composition comprising: 2 (A) at least one active agent; and 3 (B) a carrier comprising a compound having the formula 4 ; 6 N 7 0) g O OH 11 or a salt thereof.1 3. A composition as defined in claim 2, wherein said active agent is sclected 2 from the group consisting of a biclogically active agent, a chemically active agent, or a combination 3 thereof. 1 4, A composition as defined in claim 3, wherein said biologically active agent 2 comprises at least one peptide, mucopolysaccharide, carbohydrate, or lipid.oo © WO 00/06534 PCT/US99/17090 $1 5. A composition as defined in claim 3, wherein said biologically active agent 2 is selected from the group consisting of growth hormones, human growth hormones (hGH), 3 recombinant human growth hormones (rhGH), bovine growth hormone, porcine growth hormones, 4 growth hormone-releasing hormones, interferons, a-interferon, PB-interferon, vy-interferon, interleukin-1, interleukin-IT; insulin, insulin-like growth factor(IGF), IGF-1, heparin, unfractionated 6 heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular 7 weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, 8 human calcitonin, erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, 9 somatostatin, protease inhibitors, adrcnocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, 11 thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, sodium chromoglycate, 12 disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), 13 fragments of PTH, antimicrobials, anti-fungal agents, analogs, fragments, mimetics and polyethylene 14 glycol (PEG)-modified derivatives of these compounds; and any combination thereof.1 6. A composition as defined in claim 3, wherein said biologically active agent 2 is selected from the group consisting of human growth hormones (hGH), bovine growth hormone, 3 growth hormone-releasing hormones, interferons, interleukin-1, interleukin-II, insulin, heparin, low 4 molecular weight heparin, very low molecular weight heparin, calcitonin, erythropoietin (EPO), 5 atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, adrenocorticotropin, 6 gonadotropin releasing hormone, oxytocin, vasopressin, sodium chromoglycate, disodium 7 chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), antimicrobials, 8 anti-fungal agents, and any combination thereof.1 7. A composition as defined in claim 3, wherein said biologically active agent 2 comprises an interferon, interleukin-II, insulin, heparin, low molecular weight heparin, very low 3 molecular weight heparin, calcitonin, parathyroid hormone (PTH), erythropoietin (EPO), human 4 growth hormone (hGH), oxytocin, vasopressin, vancomycin, desferrioxamine (DFO), parathyroid 5 hormone, and combinations thereof.1 8. A composition as defined in claim 3, wherein said biologically active agent 2 comprises unfractionated heparin, ultra low molecular weight heparin, and combinations thereof,1 9. A composition as defined in claim 3, wherein said biologically active agent 2 comprises insulin. 1 10. A composition as defined in claim 3, wherein said biologically active agent 2 comprises parathyroid hormone. 1 Il.A composition as defined in claim 3, wherein said biologically active agent 2 comprises human growth hormone. 1 12. A composition as defined in claim 3, wherein said biologically active agent 2 comprises erythropoietin. 1 13. A composition as defined in claim 2, wherein said carrier comprises a . 2 poly(amino acid) or a polypeptide. 1 14. A dosage unit form comprising: 2 (A) acomposition as defined in claim 2; and 3 3B) ( an excipient 4 (b) a diluent, © a disintegrant, 6 (d) a lubricant, 7 (e) a plasticizer, 8 (fH a colorant, 9 (8) adosing vehicle, or (h) any combination thereof. 1 15. A dosage unit form as defined in claim 13, wherein said active agent is 2 selected from the group consisting of a biologically active agent, a chemically active agent, or a 3 combination thereof. 1 16. A dosage unit form as defined in claim 14, wherein said biologically active oo WO 00/06534 PCT/US99/17090 2 agent comprises at least one peptide, mucopolysaccharide, carbohydrate, or lipid. 1 17. A dosage unit form as defined in claim 14, wherein said biolo gically active 2 agent is selected from the group consisting of growth hormones, human growth hormones (hGH), 3 recombinant human growth hormones (thGH), bovine growth hormone, porcine growth hormones, 4 growth hormone-releasing hormones, interferons, o-interferon, f-interferon, y-interferon, interleukin-1, interleukin-I1, insulin, insulin-like growth factor(IGF ), IGE-1, heparin, unfractionated 6 heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular 7 weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, 8 human calcitonin, erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, 9 somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, 11 thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, sodium chromoglycate, 12 disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), 13 fragments of PTH, antimicrobials, anti-fungal agents, analogs, fragments, mimetics and polyethylene 14 glycol (PEG)-modified derivatives of these compounds, and any combination thereof. 1 18. A dosage unit form as defined in claim 14, wherein said biologically active 2 agent is selected from the group consisting of human growth hormones (hGH), bovine growth 3 hormone, growth hormone-releasing hormones, interferons, interleukin-1, interleukin-II, insulin, 4 heparin, low molecular weight heparin, very low molecular weight heparin, calcitonin, erythropoietin 5 (EPQ), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, adrenocorticotropin, 6 gonadotropin releasing hormone, oxytocin, vasopressin, sodium chromoglycate, disodium 7 chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), antimicrobials, 8 anti-fungal agents, and any combination thereof. 1 19. A dosage unit form as defined in claim 14, wherein said biologically active 2 agent comprises an interferon, interleukin-II, insulin, heparin, low molecular weight heparin, very 3 low molecular weight heparin, calcitonin, parathyroid hormone (PTH), erythropoietin (EPO), human 4 growth hormone (hGH), oxytocin, vasopressin, vancomycin, desferrioxamine (DFO), parathyroid 5 hormone, and combinations thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9426798P | 1998-07-27 | 1998-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200100226B true ZA200100226B (en) | 2001-09-04 |
Family
ID=27754061
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200100227A ZA200100227B (en) | 1998-07-27 | 2001-01-09 | Pulmonary delivery of active agents. |
ZA200100226A ZA200100226B (en) | 1998-07-27 | 2001-01-09 | Compounds and compositions for delivering active agents. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200100227A ZA200100227B (en) | 1998-07-27 | 2001-01-09 | Pulmonary delivery of active agents. |
Country Status (1)
Country | Link |
---|---|
ZA (2) | ZA200100227B (en) |
-
2001
- 2001-01-09 ZA ZA200100227A patent/ZA200100227B/en unknown
- 2001-01-09 ZA ZA200100226A patent/ZA200100226B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200100227B (en) | 2001-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU751612B2 (en) | Compounds and compositions for delivering active agents | |
AU2001273153C1 (en) | Compounds and compositions for delivering active agents | |
US5863944A (en) | Compounds and compositions for delivering active agents | |
US6693208B2 (en) | Compounds and compositions for delivering active agents | |
EP1156787B1 (en) | Oxadiazole compounds and compositions for delivering active agents | |
AU2001273153A1 (en) | Compounds and compositions for delivering active agents | |
WO2000050386A1 (en) | Compounds and compositions for delivering active agents | |
EP0993831A2 (en) | Compounds and compositions for delivering active agents | |
WO2002015959A2 (en) | Compounds and compositions for delivering active agents | |
US20030225300A1 (en) | Compounds and compositions for delivering active agents | |
ZA200100226B (en) | Compounds and compositions for delivering active agents. | |
MXPA01000924A (en) | Compounds and compositions for delivering active agents | |
MXPA99009632A (en) | Compounds and compositions for delivering active agents |